@article{a219e59c41f545eb8fc7953d308a8a89,
title = "Hepatitis e virus seroprevalence and correlates of anti-HEV IgG antibodies in the Rakai District, Uganda",
abstract = "A cross-sectional study was conducted of 500 human immunodeficiency virus (HIV)-infected adults frequency matched on age, sex, and community to 500 HIV-uninfected individuals in the Rakai District, Uganda to evaluate seroprevalence of anti-hepatitis E virus (HEV) IgG antibodies. HEV seroprevalence was 47%, and 1 HIV-infected individual was actively infected with a genotype 3 virus. Using modified Poisson regression, male sex (prevalence ratios [PR] = 1.247; 95% confidence interval [CI], 1.071-1.450) and chronic hepatitis B virus infection (PR = 1.377; 95% CI, 1.090-1.738) were associated with HEV seroprevalence. HIV infection status (PR = 0.973; 95% CI, 0.852-1.111) was not associated with HEV seroprevalence. These data suggest there is a large burden of prior exposure to HEV in rural Uganda.",
keywords = "HEV seroprevalence, Hepatitis E virus, Rakai, Uganda, Viral hepatitis",
author = "{the Rakai Health Sciences Program} and Denali Boon and Redd, {Andrew D.} and Oliver Laeyendecker and Engle, {Ronald E.} and Hanh Nguyen and Ponsiano Ocama and Iga Boaz and Anthony Ndyanabo and Valerian Kiggundu and Reynolds, {Steven J.} and Gray, {Ronald H.} and Wawer, {Maria J.} and Purcell, {Robert H.} and Kirk, {Gregory D.} and Quinn, {Thomas C.} and Lara Stabinski",
note = "Funding Information: We thank the laboratory and clinical staff at RHSP, for their excellence and dedication to this study. We thank Claro Yu for his invaluable advice, and the study participants whose commitment and cooperation made the study possible. We thank the Office of Cyber Infrastructure and Computational Biology (OCICB), NIAID for data management support. Lastly, we thank Sarah Wendel for managing and shipping clinical samples. This article reflects the views of the authors and should not be construed to represent FDA's views or policies. This work was supported by primarily the United States National Institutes of Health Bench to Bedside Program (2008). Additional support was provided by the Division of Intramural Research, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, the National Institute on Drug Abuse (grant number T32-DA-007292), the National Institute of Allergy and Infectious Diseases (grant number R01-AI-16078), and the American Cancer Society (grant number MRSG-07-284-01-CCE). The study was jointly conducted and benefited from close collaboration of researchers from the intramural National Institutes of Health Laboratories of Immunoregulation and Infectious Diseases, Johns Hopkins University, Makerere University, and the Rakai Health Sciences Program. Support for the RHSP HIV Care Program was provided by the President's Emergency Fund for AIDS Relief and support for the Rakai Cohort Study was provided by the Department of the Army, United States Army Medical Research and Material Command Cooperative Agreement (grant number DAMD17- 98-2-8007); National Institute of Allergy and Infectious Diseases (grant numbers R01-AI-34826 and R01-AI-34265); and National Institute of Child and Health Development (grant number 5P30-HD-06826). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Funding Information: Financial support. This work was supported by primarily the United States National Institutes of Health Bench to Bedside Program (2008). Additional support was provided by the Division of Intramural Research, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, the National Institute on Drug Abuse (grant number T32-DA-007292), the National Institute of Allergy and Infectious Diseases (grant number R01-AI-16078), and the American Cancer Society (grant number MRSG-07-284-01-CCE). The study was jointly conducted and benefited from close collaboration of researchers from the intramural National Institutes of Health Laboratories of Immunoregulation and Infectious Diseases, Johns Hopkins University, Makerere University, and the Rakai Health Sciences Program. Support for the RHSP HIV Care Program was provided by the President{\textquoteright}s Emergency Fund for AIDS Relief and support for the Rakai Cohort Study was provided by the Department of the Army, United States Army Medical Research and Material Command Cooperative Agreement (grant number DAMD17-98-2-8007); National Institute of Allergy and Infectious Diseases (grant numbers R01-AI-34826 and R01-AI-34265); and National Institute of Child and Health Development (grant number 5P30-HD-06826). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Publisher Copyright: {\textcopyright} The 2017 Author(s).",
year = "2018",
month = mar,
day = "1",
doi = "10.1093/infdis/jix610",
language = "English (US)",
volume = "217",
pages = "785--789",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",
}